Cohen's SAC Capital Faces SEC Probe Related to Biotech Trading
Tweet
Share
E-mail
Steven Cohen's SAC Capital hedge fund faces a SEC probe on whether it used insider information to profit from the 2007 takeover of biotechnology firm MedImmune Inc., according to reports from the Wall Street Journal.
The probe is part of a broader inquiry into hedge fund trading in some of the largest health-care deals of the past decade, the Journal said.
The probe is part of a broader inquiry into hedge fund trading in some of the largest health-care deals of the past decade, the Journal said.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SEC plans crypto investment regime and tokenized stock exemption - Bloomberg
- Realty Income proposes $750M convertible senior notes due 2031
- Blue Owl Capital prices $750M senior notes offering at 6.750%
Create E-mail Alert Related Categories
Hedge Funds, Trader TalkRelated Entities
SAC Capital, Steven A. Cohen, Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
